Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine for cardiac iron load in beta-thalassemia major
IRCT20250421065432N1Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in beta thalassemia comparing Amlodipine plus usual iron-chelation therapy with Placebo plus usual iron-chelation therapy (2 arms). Primary endpoints: Cardiac iron deposition, Hepatic iron deposition and 8 more. Started Feb 2026; status: recruiting.
02
Drugs
amlodipine
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on IRCT20250421065432N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250421065432N1.